Aspirin in the Treatment and Prevention of Cardiovascular Disease: Current Perspectives and Future Directions

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2007 Nov 16

PMID 18001625

Citations 9

Authors

Charles H Hennekens

Affiliations

Soon will be listed here.

Abstract

In secondary prevention among male and female survivors of prior myocardial infarction (MI), occlusive stroke, transient ischemic attack, and other high-risk conditions, long-term use of aspirin confers very similar statistically significant and clinically important reductions in MI, stroke, and cardiovascular death. In men and women suffering acute MI or acute occlusive stroke, aspirin confers similar benefits. In primary prevention, aspirin confers a statistically significant and clinically important reduction in risk of a first MI, but the data on stroke and cardiovascular disease death remain inconclusive, so aspirin should be prescribed on an individual basis by the healthcare provider who weighs this clear benefit against long-term side effects. Worldwide, aspirin used more widely and appropriately would avoid many premature deaths in secondary prevention, during acute MI, and during acute stroke, as well as many first MI in primary prevention.

Citing Articles

Acetylsalicylic Acid Reduces Passive Aortic Wall Stiffness and Cardiovascular Remodelling in a Mouse Model of Advanced Atherosclerosis.

Roth L, Rombouts M, Schrijvers D, Emini Veseli B, Martinet W, De Meyer G Int J Mol Sci. 2022; 23(1).

PMID: 35008828 PMC: 8745264. DOI: 10.3390/ijms23010404.

Erlanger Glaucoma Registry: Effect of a Long-Term Therapy with Statins and Acetyl Salicylic Acid on Glaucoma Conversion and Progression.

Thiermeier N, Lammer R, Mardin C, Hohberger B Biology (Basel). 2021; 10(6).

PMID: 34208432 PMC: 8234675. DOI: 10.3390/biology10060538.

Role of Sulforaphane in Protection of Gastrointestinal Tract Against H. pylori and NSAID-Induced Oxidative Stress.

Yanaka A Curr Pharm Des. 2017; 23(27):4066-4075.

PMID: 28176666 PMC: 5759180. DOI: 10.2174/1381612823666170207103943.

nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Parikh V, Kutlu M, Gould T Schizophr Res. 2016; 171(1-3):1-15.

PMID: 26803692 PMC: 4762752. DOI: 10.1016/j.schres.2016.01.020.

Aspirin and multiple sclerosis.

Tsau S, Emerson M, Lynch S, Levine S BMC Med. 2015; 13:153.

PMID: 26123634 PMC: 4485640. DOI: 10.1186/s12916-015-0394-4.

References

Willett W, Manson J, Stampfer M, Colditz G, Rosner B, Speizer F . Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. JAMA. 1995; 273(6):461-5. DOI: 10.1001/jama.1995.03520300035033. View

. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice.... Lancet. 1998; 351(9098):233-41. View

Pearson T, Blair S, Daniels S, Eckel R, Fair J, Fortmann S . AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association.... Circulation. 2002; 106(3):388-91. DOI: 10.1161/01.cir.0000020190.45892.75. View

. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med. 2002; 136(2):157-60. DOI: 10.7326/0003-4819-136-2-200201150-00015. View

. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed). 1988; 296(6618):316-20. PMC: 2544832. View

Ridker P, Cook N, Lee I, Gordon D, Gaziano J, Manson J . A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005; 352(13):1293-304. DOI: 10.1056/NEJMoa050613. View

Reilly I, FitzGerald G . Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987; 69(1):180-6. View

. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329):71-86. PMC: 64503. DOI: 10.1136/bmj.324.7329.71. View

. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989; 321(3):129-35. DOI: 10.1056/NEJM198907203210301. View

10.

. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486-97. DOI: 10.1001/jama.285.19.2486. View

11.

Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B . Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J. 2004; 25(2):166-81. DOI: 10.1016/j.ehj.2003.10.013. View

12.

Peto R, Chen Z, Boreham J . Tobacco--the growing epidemic. Nat Med. 1999; 5(1):15-7. DOI: 10.1038/4691. View

13.

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

14.

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

15.

. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2(8607):349-60. View

16.

Flegal K, Carroll M, Ogden C, Johnson C . Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002; 288(14):1723-7. DOI: 10.1001/jama.288.14.1723. View

17.

Nelson M, Reid C, Beilin L, Donnan G, Johnston C, Krum H . Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE). Drugs Aging. 2003; 20(12):897-903. DOI: 10.2165/00002512-200320120-00004. View

18.

Hansson L, Zanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S . Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351(9118):1755-62. DOI: 10.1016/s0140-6736(98)04311-6. View

19.

Hennekens C, Sechenova O, Hollar D, Serebruany V . Dose of aspirin in the treatment and prevention of cardiovascular disease: current and future directions. J Cardiovasc Pharmacol Ther. 2006; 11(3):170-6. DOI: 10.1177/1074248406292263. View

20.

de Gaetano G . Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet. 2001; 357(9250):89-95. DOI: 10.1016/s0140-6736(00)03539-x. View